AUTHORS
Mikhaila Rice, PharmD, James A Davis, PharmD, BCOP2, Grace Elsey, PharmD3, Baylee Bryan, PharmD4, Jessica McElwee, PharmD, BCOP5, Christy Khouderchah6, Jordan Snyder, PharmD, BCOP7, Jonathan Kissam, PharmD8, Megan Vince, PharmD, BCOP9, Lana Alhashimi, PharmD10, Ivan Huang, PharmD, BCOP11, Andrew Jay Portuguese, MD12, Danai Dima, MD13, Rahul Banerjee, MD14, Zahra Mahmoudjafari, PharmD, BCOP15, Katelynn Granger, PharmD, BCOP16, Matthew Warrick, PharmD, BCPS, BCOP17, Shebli Atrash, MD18, Doug W. Sborov, MD, MS19, Hana Kurz, PharmD, BCOP20, Kelley Julian, PharmD, BCOP21, Donald C Moore, PharmD, BCOP22, Christopher Cahoon, PharmD23, Anthony Dominick24, Jack Khouri, MD25
AFFILIATIONS
1 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
2 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
3 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
4 Huntsman Cancer Institute, Salt Lake City, Utah, United States
5 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States
7 The University of Kansas Cancer Center, Westwood, Kansas, United States
8 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
9 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
10 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States
15 The University of Kansas Cancer Center, Westwood, Kansas, United States
16 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
17 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
18 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
19 Huntsman Cancer Institute, Salt Lake City, Utah, United States
20 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
21 Huntsman Cancer Institute, Salt Lake City, Utah, United States
22 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
23 Huntsman Cancer Institute, Salt Lake City, Utah, United States
24 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
25 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
ABSTRACT
Introduction: B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAb) have demonstrated durable efficacy in patients with relapsed and refractory multiple myeloma (RRMM). Although initial studies primarily evaluated weekly BsAb dosing, prescribing information and recent trials have incorporated guidance for transitions to every two-week (Q2W) and/or every four-week dosing (Q4W) based on treatment regimen, response status, or duration of response. Real-world, de-escalation from weekly to Q2W, Q3W, or Q4W dosing may occur sooner due to clinical response or adverse effects. Outcomes of real-world dose de-escalation practices are lacking, so here we describe patterns of BCMA-directed BsAb dose de-escalation.
Methods: This multicenter, retrospective study included patients who initiated commercial elranatamab, linvoseltamab, or teclistamab at six academic institutions prior to September 30th, 2025. Outcomes included the proportion of patients with de-escalation in BsAb dosing frequency, time to de-escalation, reason for de-escalation, and re-escalation occurrence and reason. Descriptive statistics were utilized to summarize baseline demographics and outcomes. Kaplan-Meier method was used for progression free survival (PFS) and overall survival (OS) estimates.
Results: Of 475 patients included, 63 (13.3%) received elranatamab, 12 (2.5%) received linvoseltamab, and 400 (84.2%) received teclistamab. Median age was 69 years (range 32-91) and 246 (51.8%) were male. Most patients had an ECOG of 0-2 (90.7%). Patients received a median of 5 prior lines of therapy (range 1-18). Most patients received BsAb monotherapy, but seven (1.5%) received with pomalidomide, six (1.3%) received with daratumumab, and three (0.6%) received with talquetamab. Ten patients were lost-to-follow up, so de-escalation status could not be assessed; these patients were excluded from analysis.
A first de-escalation occurred in 190 (40.9%) patients, and a second de-escalation occurred in 84 (18.1%) patients. Median time to first de-escalation was 3.75 (range 0.43-15) months. Frequency after first de-escalation was Q2W in 161 (84.7%) patients, Q3W in 3 (1.6%) patients, and Q4W in 26 (13.7%) patients. Reason for first de-escalation was most commonly ongoing response (69.5%) followed by toxicity (25.3%) and toxicity prevention (17.9%) with some patients de-escalating therapy for multiple reasons. Median time from first to second de-escalation was 3.72 (range 0.89-30.8) months. Frequency after second de-escalation was Q3W in 4 (4.8%) patients, Q4W in 76 (90.5%) patients, and Q12W in 4 (4.8%) patients. Reason for second de-escalation was most commonly ongoing response (75.0%) followed by toxicity (29.8%) and toxicity prevention (16.7%) with some patients de-escalating therapy for multiple reasons. De-escalation occurred earlier than current dosing schedule requirements as outlined in prescribing information in at least 176 (92%) patients.
Median duration of follow-up after first de-escalation was 11.4 months. Ninety-five (50%) patients continued reduced-frequency BsAb treatment at the time of data cut off. Median PFS from first de-escalation was 24.9 months (95% CI 17.1-not reached) and median OS from first de-escalation was 35.0 months (95% CI 33.1-not reached). Of those with a de-escalation, 92 (48%) subsequently discontinued therapy. Reasons for discontinuation included disease progression (PD) (n=40/190, 21.1%), toxicity (n=25/190, 13.1%), ongoing response (n=14/190, 7.4%), death (n=9/190, 4.7%), or other (n=9, 4.7%) with some patients discontinuing treatment for multiple reasons. Fifteen (7.9%) of the 190 patients subsequently re-escalated to more frequent dosing, most commonly due concern for PD. Of those patients, seven (46.7%) discontinued BsAb within two months of re-escalation due to PD. Daratumumab was added to teclistamab at the point of re-escalation in one patient.
Conclusions: In this real-world cohort of patients receiving BCMA-directed BsAb, de-escalation of dosing frequency was common and frequently occurred earlier than current dosing schedule recommendations within prescribing information. Complete BsAb discontinuation due to ongoing response, while uncommon, occurred as well. BsAb re-escalation after previous de-escalation did occur in some patients due to concern for PD, but this strategy was generally unsuccessful. Future analyses are ongoing to understand the risk of infections following reductions in dosing frequency.
DISCLOSURES
Mikhaila Rice, PharmD: No relevant conflicts of interest to declare.